
Switzerland · Medical devices startup
Spineart is a Swiss medical device company founded in 2005, headquartered in Plan-les-Ouates, Geneva.
Funding reportedLast round: Venture (Round not Specified)
Follow Spineart and see its new rounds in your feed.Start following
Spineart is a Swiss medical device company founded in 2005, headquartered in Plan-les-Ouates, Geneva.
Recognized as one of the top 10 spine companies globally, Spineart focuses on innovating spine surgery through patented and clinically validated technologies. The company aims to simplify spinal surgery and enhance the standard of care for patients worldwide. Spineart offers a diverse range of procedural solutions and digital technologies for spine surgery. Their portfolio includes minimally invasive surgery solutions, motion preservation technologies like cervical disc prostheses, 3D-printed implants using proprietary Ti-LIFE technology, and innovative spinal fusion and biologics. They also provide robotic guidance and digital planning tools, fracture treatment solutions, and compact instrumentation sets. All devices are individually packaged and sterilized to ensure safety and compliance. Spineart serves spine surgeons, hospitals, and operating room teams in over 60 countries, supporting the adoption of advanced technologies to improve patient outcomes.
Funding, as reported
From Spineart's own website: 2 founders, 8 on the team.
What they build
Known for
fusion technologysurgical safety protocolshealth caremedical innovationdigital health3d printingsurgical innovationdistributionmanufacturingbarcoding technologyecential roboticssurgeon supportrobotic navigation platformorthopaedic surgeryimplant integrationspinal implants
Built with from their website
DockerAdobeContact Form 7Google Tag ManagerExcel ImpactMicrosoft Advanced Group Policy ManagementWordPress.orgMicrosoft Distributed File SystemAtlassianPWA
Power QueryHeadroom.jsMicrosoft PowerPointLinkedin Insight TagSAP Contract Lifecycle ManagementApacheMailChimpMicrosoft Windows
Add your raise, your deck and your story, and put Spineart in front of investors. Or tell us what we have wrong.